The invention relates to a safe and efficient process for the hydrolysis of α,ω-C.sub.3-10alkanediol mononitrate monoacylates. The process is safer to operators and allows to obtain advantageous yields on industrial scale.

The invention relates to a safe and efficient process for the hydrolysis of α,ω-C.sub.3-10alkanediol mononitrate monoacylates. The process is safer to operators and allows to obtain advantageous yields on industrial scale.

The invention relates to a safe and efficient process for the for the acylation of an α,ω-alkanediol, which can be used in the manufacture of ω-nitrooxy-C.sub.3-10alkane-1-ols. The process is safer to operators and allows to obtain advantageous yields on industrial scale.

The invention relates to a safe and efficient process for the for the acylation of an α,ω-alkanediol, which can be used in the manufacture of ω-nitrooxy-C.sub.3-10alkane-1-ols. The process is safer to operators and allows to obtain advantageous yields on industrial scale.

The invention relates to a safe and efficient process for the nitrate ester formation of an α,ω-C.sub.3-10alkanediol monoacylate. The process is safer to operators and allows to obtain advantageous yields on industrial scale.

The invention relates to a safe and efficient process for the nitrate ester formation of an α,ω-C.sub.3-10alkanediol monoacylate. The process is safer to operators and allows to obtain advantageous yields on industrial scale.

The present invention relates to a haloalkenyl alkoxymethyl ether compound of the following general formula (1): R.sup.1CH.sub.2OCH.sub.2OCH.sub.2CH.sub.2CH═CH(CH.sub.2).sub.aX.sup.1 (1) wherein R.sup.1 represents a hydrogen atom, an n-alkyl group having 1 to 9 carbon atoms, or a phenyl group, X.sup.1 represents a halogen atom, and “a” represents an integer of 3 to 14. The present invention also relates to processes for preparing a terminal conjugated alkadien-1-yl acetate compound of the following general formula (5): CH.sub.2═CHCH═CH(CH.sub.2).sub.aOAc (5) wherein “a” is as defined above, and Ac represents an acetyl group, and a terminal conjugated alkadien-1-ol compound of the following general formula (6): CH.sub.2═CHCH═CH(CH.sub.2).sub.aOH (6) wherein “a” is as defined above, from the haloalkenyl alkoxymethyl ether compound (1).

The present invention relates to a haloalkenyl alkoxymethyl ether compound of the following general formula (1): R.sup.1CH.sub.2OCH.sub.2OCH.sub.2CH.sub.2CH═CH(CH.sub.2).sub.aX.sup.1 (1) wherein R.sup.1 represents a hydrogen atom, an n-alkyl group having 1 to 9 carbon atoms, or a phenyl group, X.sup.1 represents a halogen atom, and “a” represents an integer of 3 to 14. The present invention also relates to processes for preparing a terminal conjugated alkadien-1-yl acetate compound of the following general formula (5): CH.sub.2═CHCH═CH(CH.sub.2).sub.aOAc (5) wherein “a” is as defined above, and Ac represents an acetyl group, and a terminal conjugated alkadien-1-ol compound of the following general formula (6): CH.sub.2═CHCH═CH(CH.sub.2).sub.aOH (6) wherein “a” is as defined above, from the haloalkenyl alkoxymethyl ether compound (1).

Cannabidiolic acid esters, compositions comprising them and uses thereof in the treatment of various diseases, conditions and symptoms.

This invention is directed to, inter alia, compounds, methods, systems, and compositions for the maintenance, enhancement, and expansion of hematopoietic stem cells derived from one or more sources of CD34+ cells. Sources of CD34+ cells include bone marrow, cord blood, mobilized peripheral blood, and non-mobilized peripheral blood. Also provided herein are compounds of Formula I ##STR00001## which are useful in maintaining, enhancing, and expanding of hematopoietic stem cells.